Liraglutide (Victoza), GLP-1 receptor agonist, is known for its ability to lower cardiovascular risk in persons with type 2 diabetes who have blood glucose values consistently above target range and who at high risk for a cardiovascular event (i.e. heart attack). What exactly mediates this benefit? Buse and colleagues uncovered that this benefit most likely is mediated by hemoglobin A1c. Please click below for additional details on this exploratory analysis.
Please share your thoughts and subscribe to receive my blogs.
#A1c #liraglutide #CV #benefit
Please share your thoughts and subscribe to receive my blogs.